Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using non-controversial adult cells. They are derived from somatic cells through reprogramming and turning on the expression of specific pluripotency genes. This reprogramming can be achieved using different techniques with varying efficiencies. [Read more…]
The Jackson Laboratory receives an up to $30 million contract award to revolutionize drug safety testing with AI-powered “virtual hearts”
New CARDIOVERSE project combines AI, stem cells, and genetic variation to predict drug safety before human trials
BAR HARBOR, Maine, Dec. 8, 2025 — Developing new drugs is one of the riskiest and most expensive endeavors in science. Today, The Jackson Laboratory (JAX) announced a bold initiative to improve that trajectory, powered by an up to $30 million contract from the Advanced Research Projects Agency for Health (ARPA-H) Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program. CATALYST is led by ARPA-H Health Science Futures Mission Office Acting Deputy Director Andy Kilianski, Ph.D.
[Read more…]
Are Stem Cells the Cure for Lower Back Pain?
Ever tossed and turned in bed, longing for relief from that nagging lower back pain? If yes, then you’re not alone. Chronic lower back pain is a common complaint and often the result of degenerative disc disease. So far, the treatment options have been pretty limited.
But what if there was an alternative approach, something that could treat the root cause of the problem? Enter stem cells. These unique cells could revolutionize how we approach treating chronic lower back pain. Interested in learning more? Read on as we unravel their potential. [Read more…]
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia
December 08, 2025, Silver Spring, MD (U.S. FDA) — The U.S. Food and Drug Administration announced that it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). Omisirge is indicated for adults and pediatric patients 12 years and older with hematologic malignancies and now is approved for adults and pediatric patients six years and older with SAA following reduced intensity conditioning and for whom a compatible donor is not available. [Read more…]
Stem Cell Infusion: What to Expect
In recent years, stem cell infusion has become a breakthrough technology. There have been multiple medical leaders citing regenerative medicine as the way of the future. Stem cells obviate our need to patch up the body or create stopgap measures for systems that don’t work. They instead promise to replace organs and tissues that no longer function, essentially rebuilding the body from the inside out. Naturally, science has not progressed to the point of spreading this technology across the globe. However, the growing availability and efficacy of stem cell infusion indicate this isn’t far off, either. [Read more…]
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 339
- Next Page »